论文部分内容阅读
目的:研究吴茱萸碱的抗肝纤维化作用。方法:雄性C57鼠采用腹腔注射CCl4构建肝纤维化模型,同时采用吴茱萸碱(18mg/kg、9mg/kg)、扶正化瘀胶囊(750mg/kg)进行灌胃给药,干预运HE染色检测肝纤维化的变化;生化检测血清丙氨酸转移酶(ALT)和天冬氨酸转移酶(AST),以及肝组织的SOD、MDA含量;Western blot法检测转化生长因子β(TGF-β)及血小板衍生生长因子(PDGF)的蛋白表达。结果:吴茱萸碱(18mg/kg、9mg/kg)组和扶正化瘀胶囊(750mg/kg)组显著抑制CCl4诱导的小鼠肝纤维化程度,血清ALT、AST水平及肝脏组织中MDA水平明显降低,SOD显著提高;吴茱萸碱(18mg/kg、9mg/kg)组和扶正化瘀胶囊(750mg/kg)组显著抑制肝组织中TGF-1和PDGF的蛋白表达。结论:吴茱萸碱具有显著的改善肝纤维化作用。
Objective: To study the anti-hepatic fibrosis effect of evodiamine. Methods: Male C57 rats were injected intraperitoneally with CCl4 to establish a model of hepatic fibrosis. At the same time, Evodiamine (18mg / kg, 9mg / kg) and Fuzhenghuayu Capsule (750mg / kg) Fibrosis, biochemical changes of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and liver tissue SOD, MDA content; Western blot detection of transforming growth factor β (TGF-β) and Platelet-derived growth factor (PDGF) protein expression. Results: Evodiamine (18mg / kg, 9mg / kg) and Fuzhenghuayu Capsule (750mg / kg) significantly inhibited the hepatic fibrosis in mice induced by CCl4, the levels of serum ALT and AST and the levels of MDA in liver tissue were significantly decreased , SOD significantly increased; Evodiamine (18mg / kg, 9mg / kg) group and Fuzhenghuayu Capsule (750mg / kg) group significantly inhibited the expression of TGF-1 and PDGF in liver tissue. Conclusion: Evodiamine has a significant effect on improving hepatic fibrosis.